Skip to Menu Skip to Search Contact Us India Websites & Languages Skip to Content

SGS announced today that the company has recently opened its second Life Science Services laboratory in India at Navi Mumbai in Maharashtra. SGS’s decision to further invest in an additional analytical laboratory was driven by the booming local demand from large generic and multinational pharmaceutical companies around the major pharmaceutical hub of Mumbai.

The new 15,000 ft2 laboratory in Mumbai enhances the current service portfolio offering in India by adding 10,600 ft³ of stability storage space giving SGS the largest pharmaceutical stability capacity in India. Additionally, the facility brings to the region the latest generation Q-TOF Quadrupole Mass Spectrometer for performing Extractables and Leachables studies. In addition to microbiological testing, in-process sample testing and water system validation, the new site will also develop some capabilities to test biopharmaceuticals for mycoplasma and endotoxin.

“We are pleased that the realization of the Mumbai laboratory was done within a short timeframe.”, said Anne Hays, Executive Vice President for SGS Life Science Services. “This new analytical laboratory demonstrates SGS’s commitment to serve the growing demand in the India market and to support the development of the top western pharma companies that have operations in Mumbai – many of which are already SGS clients in other regions.” As a result of its initiative to open this new facility, SGS recently entered into a preferred partnership with one such multinational pharmaceutical firm with a Mumbai subsidiary.

Speaking on the occasion, Paul House, Managing Director, SGS India said “This lab represents great collaboration between SGS, its clients and its suppliers. That collaboration enables us to deliver world class solutions with speed. This project took 12 weeks from the day we broke ground until the day we opened for business. Critical to that speed of delivery was the feedback we took from key clients to ensure we built a facility that met their needs.”
“The pharma sector in the western part of India has been growing steadily with both an international and domestic focus” shared Arun Janakiraman, Business Director, Life Science Services, SGS India. He added, “A year ago, our customers outlined their needs for a multinational lab with expertise and advanced analytical capability to support their growing business strategy. We conceptualised our Navi Mumbai lab based on this requirement. Our customers can now tap into our global best practices, our global quality management system, and partner with SGS to offer services that were previously difficult to perform in India or were not cost effective”

SGS began its Life Science Services operations from its current Chennai facility in 2005 to provide analytical support to the rapidly growing pharmaceutical industry in India. This laboratory is ISO 17025 and GMP certified. Additionally, the Chennai facility has achieved prequalified status from the WHO in early 2011 and is US-FDA registered and inspected.

With 18 laboratories offering contract analytical and bioanalytical services, SGS leverages its strong global network to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides clinical trial management (Phase I to IV) and services encompassing clinical pharmacology studies, data management, pharmacovigilance and regulatory consultancy.





SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognised as the global benchmark for quality and integrity. With more than 70,000 employees, SGS operates a network of over 1,350 offices and laboratories around the world.